[ back to News ]

Concert Pharmaceuticals to Present at First Annual Boston Biotech R&D Conference

October 15, 2008

Lexington, MA – Concert Pharmaceuticals, Inc. today announced that it will be presenting at the 2008 Boston Biotech R&D Conference being held at Harvard Medical School in Cambridge, Massachusetts.  Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present an overview of the Company on Wednesday, October 22, 2008 at 2:20 p.m. (ET).

About Concert

Concert Pharmaceuticals, Inc. is a clinical stage biotechnology company dedicated to creating medically and commercially important new medicines through a novel approach utilizing the naturally-occurring element deuterium.  Concert applies its innovative platform to create highly differentiated compounds based on well-understood biological targets and drug molecules, yielding a rich pipeline of new chemical entities (NCEs).  By leveraging decades of pharmaceutical experience to design NCEs from proven therapies, Concert’s drug candidates have potential for first-in-class use in under-served medical conditions, as well as best-in-class efficacy and safety, while reducing R&D risk, time, and expense. The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including vasomotor symptoms, HIV/AIDS and fibrotic diseases, among others.  Since its inception in 2006, Concert has raised more than $96 million and has been financed by leading venture capitalists and institutional investors.  A complete listing of Concert’s shareholders and additional corporate information is available online at http://www.concertpharma.com.

About the Boston Biotech R&D Conference

The 2008 Boston Biotech R&D Conference will take place at Harvard Medical School and will highlight the work of top academics as well as up-and-coming biotechnology companies in the Boston area.  The agenda features keynotes from several luminaries in medicine and research, including Jeffrey S. Flier, Dean of Harvard Medical School, Leonard Guarente, Ronald Kahn, Eric S. Lander, Robert Langer, Phillip Sharp, David Sinclair, as well as CEOs of the next generation of leading biotechnology and pharmaceutical companies from the Boston area. The conference is sponsored by Alexandria Real Estate Equities Inc., Pure Communications Inc., and Rodman & Renshaw, LLC.  For more information, visit www.bostonbiotechconference.com.

CoNCERT and CoNCERT Pharmaceuticals are trademarks of Concert Pharmaceuticals, Inc.

[ back to top ]